Congress Materials - United European Gastroenterology (UEGW 2025)
2025 United European Gastroenterology | Oct 4-7 | Berlin, Germany
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Benefit-risk of guselkumab compared to placebo in the treatment of moderately to severely active ulcerative colitis
Janssen, Baker, Yee, Li, Miao, Germinaro
This document will be available on October 7th 2025
Comparative efficacy of guselkumab vs. risankizumab in induction phase for Crohn’s disease: an anchored MAIC analysis
Van Sanden, Trevisan, Strobl, Wirth
This document will be available on October 7th 2025
Comparison of pharmacodynamic serum IL-22 and the mechanistic tissue molecular changes between guselkumab subcutaneous and intravenous induction in moderately active crohn’s disease: post-hoc analysis of the GRAVITI and GALAXI phase 3 studies
Sohn, Richards, Patel, Hart, Sisk, Olurinde, Terry, McRae, Reinisch, Steinwurz, Panaccione, D'Haens, Branigan
This document will be available on October 7th 2025
Earlier use of guselkumab is projected to yield long-term sustained remission in patients with moderate-to-severe ulcerative colitis
Dimova, Keng, Naessens, Kachroo, Adsul, Gomez, Wu
This document will be available on October 7th 2025
Effect of guselkumab subcutaneous induction and maintenance on symptoms of moderately to severely active ulcerative colitis as measured by the UC-PRO/SS: results from the phase 3 ASTRO study
Danese, Peyrin-Biroulet, Long, Germinaro, Baker, Alvarez, Kavalam, Han, Jorgens, Jiang, Zhang, Hisamatsu, Rubin, Allegretti
This document will be available on October 7th 2025
Effects of subcutaneous guselkumab induction and maintenance on histologic outcomes in patients with moderately to severely active crohn’s disease in GRAVITI, a phase 3 double-blind, placebo-controlled, treat-through study
D’Haens, Hart, Panaccione, Steinwurz, Cao, Olurinde, Salese, Branigan, Van Duijnhoven, Terry, Danese, Hisamatsu, Sands
This document will be available on October 7th 2025
Efficacy and safety of subcutaneous guselkumab induction and maintenance therapy in patients with ulcerative colitis: results through week 48 from the phase 3 ASTRO study
Allegretti, Peyrin-Biroulet, Long, Germinaro, Baker, Kavalam, Alvarez, Hertzog, Jorgens, Zhang, Jiang, Hisamatsu, Rubin, Danese
This document will be available on October 7th 2025
Efficacy and safety of subcutaneous guselkumab rescue therapy in patients with moderately to severely active Crohn’s disease and inadequate response to ustekinumab: results from GALAXI 1, 2, & 3 long-term extension
Afzali, Wolf, Leong, Van Rampelbergh, Van Duijnhoven, Busse, Hisamatsu, Panés
This document will be available on October 7th 2025
Efficacy by baseline disease characteristics of intravenous and subcutaneous guselkumab induction therapy in patients with moderately to severely active crohn’s disease: results at week 12 from the phase 3 GALAXI and GRAVITI studies
Sands, Hisamatsu, Afzali, Terry, Olurinde, Van Rampelbergh, Yee, Van Duijnhoven, Hart, Danese, Panaccione
This document will be available on October 7th 2025
Efficacy of guselkumab for small bowel lesions using balloon assisted enteroscopy: a phase 3, open-label, multicenter study
Omori, Ohtsuka, Watanabe, Kobayashi, Hosoe, Esaki, Matsuda, Sakamoto, Masuda, Chinen, Horio, Yoshigoe, Hisamatsu
This document will be available on October 7th 2025
Efficacy of guselkumab in moderately to severely active ulcerative colitis by extent of disease and inflammatory burden: subgroup analysis of the phase 3 QUASAR maintenance study
Allegretti, Hisamatsu, Bressler, Peyrin-Biroulet, Germinaro, Yarandi, Shipitofsky, Miao,Sands, Rubin, Dignass
This document will be available on October 7th 2025
Endoscopic patient clustering to investigate differential treatment effects of guselkumab and ustekinumab in crohn’s disease: post-hoc analysis of GALAXI and GRAVITI trials
Richards, Seridi, Sohn, Mcrae, Terry, Vetter, Cua, Branigan, Reinisch, Atreya
This document will be available on October 7th 2025
Guselkumab maintenance dose regimens in patients with high disease activity and severity: subgroup analysis of participants with moderately to severely active Crohn’s disease in the GALAXI phase 3 studies
Afzali, Hisamatsu, Rubin, Terry, Van Rampelbergh, Yee, Wan, Yang, Reinisch, Sands, Danese, Panaccione
This document will be available on October 7th 2025
Guselkumab pharmacokinetics and exposure-response relationships are consistent following intravenous versus subcutaneous induction in participants with Crohn’s disease
D’Haens, Adedokun, Yang, Sands, Danese, Terry, Olurinde, Van Rampelbergh, Vetter, Hisamatsu, Panaccione
This document will be available on October 7th 2025
Guselkumab versus risankizumab as maintenance treatment for moderately to severely active ulcerative colitis: Network meta-analyses of clinical remission and endoscopic outcomes
Wu, Naessens, Gomez, Bonner, Jones
This document will be available on October 7th 2025
Icotrokinra, a targeted oral peptide that selectively blocks il-23 receptor activation, in moderately to severely active ulcerative colitis: week 12 results from the phase 2b, randomized, double-blind, placebo-controlled, treat-through, dose-ranging ANTHEM-uc trial
Abreu, Siegmund, Surace, Erondu, Chen, Chachu, Louis, Matsuoka, Limdi, Arthur, Houck, Frustaci, Zou, Rydzewska, Loftus, Jairath
This document will be available on October 7th 2025
Impact of subcutaneous guselkumab therapy on molecular inflammation in patients with ulcerative colitis: results from phase 3 ASTRO study
Venkat, Sridhar, Shaikh, Sohn, Liu, Sisk, McRae, Alvarez, Baker, Germinaro, Allegretti, Long, Rubin, Peyrin-Biroulet, Hart, Branigan
This document is available on October 7th 2025
Maintenance of endoscopic and histologic improvements with guselkumab for ulcerative colitis at week 92 of the QUASAR long-term extension study
Hisamatsu, Panés, Magro, Lichtenstein, Allegretti, Bressler, Afif, Samaan, Ye, Yarandi, Germinaro, Shipitofsky, Pandya, Miao, Zhang, Dignass, Rubin, Sands
This document will be available on October 7th 2025
Molecular differentiation of guselkumab and ustekinumab in moderately to severely active Crohn’s disease: post hoc analysis of the GALAXI 2 and 3 phase 3 studies
Richards, Sohn, Zeeman, Patel, McRae, Terry, M. Vetter, W. Reinisch, D. Cua, P. Branigan
This document is available on October 7th 2025
Therapeutic and hospitalisation outcomes after first-line anti-TNF in inflammatory bowel disease: insights from the EPITHERA study using data from the French national health data
Kirchgesner, Peyrin-Biroulet, Gautier, Sosnowiez, Chaalal, Clevy, Omichessan, Cohignac, Rabiéga, Bizouard, Nishikawa, Huguet, Vuitton
This document will be available on October 7th 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
